Effects of antiglaucoma drugs on the ocular surface in rabbits: a fixed-combination drug versus two concomitant drugs

Cho, Hyun Kyung; Park, Myoung Hee; Moon, Jooho

doi:10.1007/s10384-011-0078-3

Cited by 5 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is possible that the lack of differences found in our study was due to the fact that our patients presented with either none or only mild corneal disorders before being switched to TTFC therapy. Many of the patients with glaucoma use the same or more than two kinds of anti-glaucoma ophthalmic solutions [3], and Cho et al [23] reported that a fixed-combination anti-glaucoma ophthalmic solution is beneficial in reducing adverse ocular surface changes in long-term use. Consequently, TTFC may be a better choice for glaucoma treatment over the long term.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy

Kashiwagi

2012

Jpn J Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy

Kashiwagi

2012

Jpn J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…The fixed combination was proven effective and well-tolerated in terms of symptoms, whereas improving the quality of life could also explain the increased treatment compliance [41,42]. In addition, experimental rabbit models highlight that the fixed combination medication with a lower concentration of preservatives reduces the ocular surface changes [43].…”

Section: Discussionmentioning

confidence: 99%

Fixed versus Unfixed Combination of Topical Latanoprost/Timolol for Glaucoma: An Observational Study Investigating the Level of Adherence and Ocular Surface Health

Toumanidou

Diafas

Georgiadis

et al. 2023

JCM

View full text Add to dashboard Cite

Purpose: To investigate the effect of fixed combination versus concomitant unfixed topical glaucoma treatment on patients’ adherence and ocular surface health. Patients and Methods: This is a 6-month, prospective, parallel-group, observational study in patients with ocular hypertension (OHT), primary open-angle glaucoma (POAG), or exfoliation glaucoma (XFG). A total of 142 patients with similar baseline characteristics were enrolled in this study. Seventy-one patients received a Latanoprost 0.005%/Timolol 0.5% fixed combination in the evening, whereas seventy-one patients received the unfixed treatment with Latanoprost 0.005% in the evening and Timolol 0.5% twice daily. The primary outcome was the adherence rate at baseline, and at the 3- and 6-month follow-up visits. The secondary outcomes included the signs of ocular surface disease (OSD) and intraocular pressure (IOP). Results: The adherence of patients treated with the fixed combination was higher than the unfixed treatment at the 3-month (78.0% vs. 63.0%, p < 0.001) and at the 6-month visits (73.0% vs. 58.5%, p < 0.01). The Break-up Time, Schirmer test, and Van Bijsterveld score were worse in the unfixed group at baseline and all subsequent examinations (p < 0.05 for all comparisons). There were no differences in the mean IOP between groups at baseline, 1-, and 3-month visits. IOP appears higher in the unfixed group at 6 months (16.7 vs. 15.0 mmHg, p < 0.01). Conclusion: The patients with ocular hypertension and primary open-angle glaucoma treated with a fixed combination are significantly more adherent and show a healthier ocular surface than those treated with an unfixed combination. The study provides significant evidence of the benefits of fixed combination treatment.

show abstract

“…Cho et al [ 13 ] reported that a fixed-combination antiglaucoma ophthalmic solution was beneficial for reducing adverse ocular surface changes during long-term use. We previously compared ocular adverse effects between PGA monotherapy and travoprost-Tim fixed-combination therapy with the same protocol used in the present study, and we reported no significant difference in ocular adverse effects between the two groups [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy

Kitamura

Chiba

Mabuchi

et al. 2018

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose To assess the efficacy and safety of switching from prostaglandin analog (PGA) monotherapy to tafluprost/timolol fixed-combination (Taf/Tim) therapy. Subjects and Methods Patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who had received PGA monotherapy for at least 3 months were enrolled. Patients were examined at 1, 2, and 3 months after changing therapies. Subsequently, the patients were returned to PGA monotherapy. The examined parameters included intraocular pressure (IOP) and adverse events. A questionnaire survey was conducted after the switch to Taf/Tim therapy. Results Forty patients with a mean age of 66.5 ± 10.3 years were enrolled; 39 of these patients completed the study protocol. Switching to Taf/Tim significantly reduced the IOP from 18.2 ± 2.6 mmHg at baseline to 14.8 ± 2.5 mmHg at 1 month, 15.2 ± 2.8 mmHg at 2 months, and 14.9 ± 2.5 mmHg at 3 months (P < 0.001). Switching back to the original PGA monotherapy returned the IOP values to baseline levels. Taf/Tim reduced the pulse rate insignificantly. No significant differences were observed in blood pressure, conjunctival hyperemia, or corneal adverse events. A questionnaire showed that the introduction of Taf/Tim did not significantly influence symptoms. Conclusions Compared with PGA monotherapy, Taf/Tim fixed-combination therapy significantly reduced IOP without severe adverse events.

show abstract

Effects of antiglaucoma drugs on the ocular surface in rabbits: a fixed-combination drug versus two concomitant drugs

Abstract: A fixed-combination antiglaucoma drug is beneficial in reducing adverse ocular surface changes in long-term use. This is believed to be due to the smaller concentration of preservatives contained in the fixed-combination drug.

Cited by 5 publications

References 24 publications

Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy

Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy

Fixed versus Unfixed Combination of Topical Latanoprost/Timolol for Glaucoma: An Observational Study Investigating the Level of Adherence and Ocular Surface Health

Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy

Contact Info

Product

Resources

About